Jared Rutter News Today

$2 million in total funds will accelerate interdisciplinary neurobiology research and scale up a search for new rules of human biochemistry.

University of Utah President Taylor has convened 14-member Viewpoint Representation and Expression Task Force to study these issues and to make recommendations

University of Utah President Taylor Randall has empaneled a task force charged to explore what happens when students, faculty and staff are uncomfortable expressing their points of view.

University of Utah President Taylor Randall has empaneled a task force charged to explore what happens when students, faculty and staff are uncomfortable expressing their points of view. The task force has been asked to review this question and develop recommendations that “strengthen our campus climate so that all voices and perspectives are welcomed and respected,” according to Randall’s letter to task force members, which was released on Monday. The 14-member Viewpoint ...

Every minute of every day, our body adapts to meet the needs of each moment. When we binge on carbs, exercise, or become sick, chemical reactions inside our cells switch on, slow down, or shift strategy so that we have the energy and strength we need.

Scientists at University of Utah Health led research that opens up a whole new world within our cells. Their study, published in Science, uncovers a vast network of interactions that assist cells in adjusting in real time to withstand stresses on our health.

Age-related declines in stem cell function can be reversed by a 24-hour fast, according to a new study from MIT. Biologists found fasting dramatically improves stem cells’ ability to regenerate, in both aged and young mice.

Spurred by the so-called replication crisis, researchers are embracing a new culture of transparency.

Atavistik Bio is one of several companies discovering and developing drugs that work by allostery, binding to less obvious sites of a target protein. Acting CEO John Josey said the startup aims to stand apart with its focus on understanding metabolic interactions, a path less trodden by others in allosteric drug discovery.

Share this article Share this article CAMBRIDGE, Mass., July 15, 2021 /PRNewswire/ -- PAQ Therapeutics, a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, today announced the completion of its $30 million Series A financing. PAQs approach and technology expands the therapeutic potential of autophagy - the bodys most versatile mechanism for natural cellular degradation – to target not only disease-causing proteins but lipids, pathogens a...